Lyell 8-K: Q2 2025 Financial Results Furnished, Not Filed

Rhea-AI Filing Summary

Lyell Immunopharma announced that it issued a press release reporting its financial results for the quarter ended June 30, 2025, and attached that release as Exhibit 99.1 to this Form 8-K. The filing states the information is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly referenced. The document also lists the company’s common stock as LYEL on the NASDAQ Global Select Market and is signed on behalf of the company by Mark Meltz, General Counsel and Corporate Secretary.

Positive

• The company furnished a press release announcing its financial results for the quarter ended June 30, 2025 and attached it as Exhibit 99.1 to the Form 8-K.
• The filing lists the company’s common stock as LYEL on the NASDAQ Global Select Market, confirming exchange and ticker information in the disclosure.

Negative

• The 8-K itself contains no financial figures or operating metrics; readers must consult Exhibit 99.1 (the press release) for the actual results.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishing Q2 results; document contains no financial figures and is informational rather than a formal filing.

The Form 8-K notifies the market that Lyell furnished a press release with its quarterly results for the period ending June 30, 2025, and attached that release as Exhibit 99.1. Because the company expressly characterizes the content as "furnished" and not "filed," the disclosure limits Section 18 liability and does not automatically become part of other SEC filings. On its own, this 8-K is neutral: it confirms disclosure occurred but does not supply numbers or forward-looking commentary within the filing text.

Corporate Governance Expert

TL;DR: The company followed standard disclosure practice by furnishing a press release and noting it is not filed, which preserves certain legal protections.

Marking the press release as furnished rather than filed is a routine governance step that limits the company’s exposure to Section 18 liabilities for the content of the release. The 8-K also transparently identifies the attached exhibits (Exhibit 99.1 and the interactive cover page), the trading symbol LYEL, and the corporate officer executing the report, which satisfies basic SEC current-report disclosure requirements without introducing new substantive financial detail into the filing itself.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001806952false00018069522025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________________________________

FORM 8-K

______________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

______________________________________________

Lyell Immunopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

______________________________________________

Delaware

001-40502

83-1300510

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

201 Haskins Way

South San Francisco, California

94080

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 695-0677

(Former Name or Former Address, if Changed Since Last Report)

Not Applicable

______________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

LYEL

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release Dated August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

									Lyell Immunopharma, Inc.
Date:			August 12, 2025			By:			/s/ MARK MELTZ
									Mark Meltz
									General Counsel and Corporate Secretary

FAQ

What did Lyell (LYEL) report in this Form 8-K?

The company issued a press release announcing its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to the Form 8-K.

Does the 8-K include the actual financial results numbers?

No. The Form 8-K furnishes a press release but the filing text does not include financial figures; the press release (Exhibit 99.1) contains the results.

Is the information in the filing considered "filed" with the SEC?

The company states the information is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

What exhibits are attached to this 8-K?

The filing references Exhibit 99.1 (the press release dated August 12, 2025) and 104 (the cover page interactive data file).

Who signed the Form 8-K for Lyell?

The Form 8-K is signed on behalf of the company by Mark Meltz, General Counsel and Corporate Secretary.